NCT06429930 - Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

L608 Liposomal inhalation solution

Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.

DRUG

Placebo Solution

Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.

Trial Locations (1)

8011

RECRUITING

NZCR Ltd (New Zealand Clinical Research), Christchurch